Hanmi Pharm secures exclusive global rights to its UCN2‑based obesity therapy with Genentech in a deal worth up to $2.3 billion
Executive summary: Hanmi Pharm granted Genentech exclusive worldwide rights to develop and commercialize HM17321, a UCN2 analog for obesity, in a deal valued at up to $2.3 billion comprising upfront, milestone and royalty payments. The agreement provides Hanmi with substantial near‑term cash and validates its obesity pipeline, while Genentech gains a differentiated therapeutic option in a crowded weight‑loss market.
Who is involved: Hanmi Pharm (South Korea) and Genentech (a wholly owned subsidiary of Roche, United States).
Likely next: Hanmi will pursue clinical milestones triggering payments; Genentech is expected to advance HM17321 into Phase II trials and eventually seek regulatory approval.
Hanmi Pharm and Genentech announced an exclusive licensing agreement for HM17321, a proprietary urocortin‑2 analog targeting chronic weight management. The agreement includes upfront payments, milestone obligations and tiered royalties tied to net sales, with a total potential value of $2.3 billion. The deal validates Hanmi’s pipeline while giving Genentech a novel obesity candidate to complement its metabolic franchise.
Timeline
- — Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy (PR Newswire)
Analysis — what this means
Sectors affected
- Obesity therapeutics
- Biopharmaceutical licensing